Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting

Recruiting Observational Study
Cirrhosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 70
Sex
Any
Study type
Observational
Participants needed
40 (estimated)
Sponsor
The Cleveland Clinic · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Cirrhosis is characterized by loss of muscle as well as fat mass, which increases morbidity and mortality before, during, and after liver transplantation. A common mechanism for the reduced muscle and fat mass in cirrhosis is an increased expression of the TGF (transforming growth factor)beta superfamily member, myostatin, in the muscle and adipose tissue. The present study will examine the expres…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age 18-70 years * Patients undergoing abdominal surgery (liver transplantation or other surgery) Control 1. non liver transplant donor 2. Elective abdominal surgery (cholecystectomy, diverticulosis, acute gastrointestinal bleeding in the absence of exclusion criteria) Exclu…
Contacts

Annette Bellar, MSLA

216-636-5247

bellara@ccf.org

CONTACT

Revathi Penumatsa

penumar@ccf.org

CONTACT